Table 1.
Demographic and clinical characteristic study and control group.
| Study Group n = 142 |
Control Group n = 36 |
p-Value | |
|---|---|---|---|
| Age years median (IQR) | 54 (43–63) | 48 (45–62) | ns |
| Sex male n (%) | 83 (58.45) | 21 (58.3) | ns |
| CCI median (IQR) | 4 (2–5) | 0.5 (0–1) | <0.001 |
| Serum creatinine mg/dl median (IQR) | 1.35 (1.12–1.7) | ||
| BMI kg/m2 median (IQR) | 25 (22.55–28.37) | ||
| Primary nephropathy n (%) Unknown Glomerulonephritis ADPKD Other |
36 (25.35) 36 (25.35) 21 (14.79) 35 (24.65) |
||
| Transplant vintage years median (IQR) | 8 (3.5–15) | ||
| Deceased donor n (%) | 133 (93.7) | ||
| Immunosuppression protocol n (%) Protocol without steroids Protocol without MMF/MPS Protocol with induction |
12 (8.5) 30 (21.13) 37 (26.06) |
||
| mRNA-1273 vaccination n (%) | 37 (26.06) | 0 (0) | 0.002 |
| mRNA BNT162b2 vaccination n (%) | 105 (73.94) | 36 (100) | 0.002 |
Legend: CCI; Charlson comorbidity index; BMI, body mass index; ADPKD, autosomal dominant polycystic kidney disease; MMF/MPS, mycophenolate mofetil/Na.